Hong Kong Stock Anomaly | China Antibody-B(03681) rises over 5% again SM17 preclinical research highlights strong potential for treating CRSwNP and IPF

Caitong Finance APP learned that China Antibody-B (03681) rose more than 5% again. As of the time of writing, it increased by 4.62%, trading at HKD 2.04, with a turnover of HKD 13.3618 million.

On the news front, China Antibody announced that its first-in-class anti-IL-17RB antibody SM17 preclinical study has been published in the Journal of European Respiratory Society - Open Research. The study shows that SM17 significantly improves the pathological features of chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF) by dual inhibition of Th2/Th17 pathways and anti-fibrotic activity, supporting its potential as a transformative therapy.

Chairman, Executive Director, and CEO of China Antibody, Liang Ruian, stated, “We are very pleased that our preclinical study of SM17 has been published in the Journal of European Respiratory Society - Open Research, highlighting its potential to treat CRSwNP and IPF. These results indicate that SM17 is a highly promising first-in-class biologic targeting the key upstream alarm cytokine IL-25. By simultaneously targeting Th2 inflammation, Th17 differentiation, and fibrosis, SM17 may offer a multifaceted treatment approach for CRSwNP and IPF, with the potential to address unmet needs caused by limitations of current downstream effector therapies.”